4 HealthTech Stocks Trending Now VIR stock, SRRK stock, ARWR stock, MRUS stock
Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at dailymarketmovers.com, will continue to monitor these healthtech companies to see if the momentum continues. DailyMarketMovers.com is also looking into these tickers DAWN, COGT, RMD, BSX, RACE, RTX..
Recent VIR Stock Price: $12.66
Summary: Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States.
Salveen Richter analyst at Goldman Sachs reiterates coverage on Vir Biotechnology, Inc. (VIR) stock in the energy sector with a Buy rating and has set VIR's stock price target at $28.
TipRanks.com reports that Vir Biotechnology, Inc. currently has 5 analysts offering 12-month price targets on VIR and the consensus is a Hold rating with an average stock price target of $17.80. The most recent VIR stock price we have is $12.66 and we are not making any VIR forecasts at this time.
In addition, TradingView issued a rating for VIR over the next month, Barchart.com has a buy rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on VIR. dailymarketmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on VIR, please click here >>
Scholar Rock Holding Corporation, SRRK
Recent SRRK Stock Price: $9.83
Summary: Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States.
Srikripa Devarakonda analyst at Truist Financial reiterates coverage on Scholar Rock Holding Corporation (SRRK) stock in the energy sector with a Buy rating and has not provided SRRK's stock price target.
TipRanks.com reports that Scholar Rock Holding Corporation currently has 3 analysts offering 12-month price targets on SRRK and the consensus is a Buy rating with an average stock price target of $29.00. The most recent SRRK stock price we have is $9.83 and we are not making any SRRK forecasts at this time.
In addition, TradingView issued a rating for SRRK over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on SRRK. dailymarketmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SRRK, please click here >>
Arrowhead Pharmaceuticals, Inc., ARWR
Recent ARWR Stock Price: $25.24
Summary: Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.
Andrea Tan analyst at Goldman Sachs reiterates coverage on Arrowhead Pharmaceuticals, Inc. (ARWR) stock in the energy sector with a Hold rating and has set ARWR's stock price target at $31.
TipRanks.com reports that Arrowhead Pharmaceuticals, Inc. currently has 5 analysts offering 12-month price targets on ARWR and the consensus is a Buy rating with an average stock price target of $56.00. The most recent ARWR stock price we have is $25.24 and we are not making any ARWR forecasts at this time.
In addition, TradingView issued a rating for ARWR over the next month, Barchart.com has a sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on ARWR. dailymarketmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ARWR, please click here >>
Merus N.V., MRUS
Recent MRUS Stock Price: $52.40
Summary: Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.
Tazeen Ahmad analyst at Bank of America Securities reiterates coverage on Merus N.V. (MRUS) stock in the energy sector with a Buy rating and has set MRUS's stock price target at $76.
TipRanks.com reports that Merus N.V. currently has 5 analysts offering 12-month price targets on MRUS and the consensus is a Buy rating with an average stock price target of $82.00. The most recent MRUS stock price we have is $52.40 and we are not making any MRUS forecasts at this time.
In addition, TradingView issued a rating for MRUS over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on MRUS. dailymarketmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on MRUS, please click here >>
The editors at dailymarketmovers.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
DailyMarketMovers.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to DailyMarketMovers.com.
==============================================================================